Mindset Pharma Inc (CSE:MSET, OTCQB:MSSTF, FRA:9DF) (CSE:MSET) (OTCQB:MSSTF) (FRA:9DF) CEO James Lanthier and Joseph Araujo joined Proactive to speak about the group's positive safety data from preclinical studies on its Family 4 group of DMT analogs.
Lanthier and Araujo say that head-to-head preclinical comparisons indicated the novel DMT/5-MeO-DMT-inspired analogs showed a significant decrease in serotonergic toxicity, which can cause a range of mild to life-threatening symptoms, reaffirming the company’s previous findings that its Family 4 drug candidates demonstrated superior efficacy compared to 5-MeO-DMT.